Shionogi & Co ( (SGIOF) ) has released its Q3 earnings. Here is a breakdown of the information Shionogi & Co presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shionogi & Co., Ltd., based in Tokyo, is a prominent pharmaceutical company engaged in the research, development, and distribution of prescription drugs, with a strong emphasis on infectious disease treatments.
In its latest earnings report for the nine months ending December 31, 2024, Shionogi & Co. disclosed a slight decline in revenue of 1.0% year-on-year, amounting to 333.6 billion yen. However, the company noted a 5.2% increase in profit attributable to owners of the parent, reaching 133.8 billion yen, showcasing resilience in challenging market conditions.
The report highlighted several key financial metrics, including a decrease in operating profit by 6.9% to 129.2 billion yen, largely due to increased research and development expenses and foreign exchange impacts. Despite a decline in domestic drug sales, Shionogi experienced a notable 18.8% growth in overseas sales, particularly in North America and Europe. Additionally, royalty income increased significantly by 25.3%, contributing to the overall stable financial performance.
Looking ahead, Shionogi & Co. maintains its financial forecast for the fiscal year ending March 31, 2025, anticipating a 5.7% increase in revenue to 460 billion yen and a 5.5% rise in profit attributable to owners of the parent. The company remains focused on expanding its geographical reach and product portfolio in the global market.
